Subscribe to our Newsletters !!
Although copying the blueprint is extremely comple
Eppendorf is expandin
The recent rabies death of an 11 year old Canadian
Zydus Lifesciences Limited (Zydus), in partnership
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Micr
Siberia’s Vector virology institute on September 8 finished early-stage human trials, called Phase II, of a second possible Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.
Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August after finishing early-stage human trials.
“Today… the last group of 20 volunteers was released from hospital,” watchdog Rospotrebnadzor said in a statement.
“All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling great.”
